The first half of 2018 brought with it a number of practice-changing data in oncology, including some major advances that were presented at the American Association of Cancer Research (AACR) and American Society of Clinical Oncology (ASCO) annual meetings.
Immunotherapy continues to be at the forefront of many discussions, but advances with other targeted therapies are also making an impact.
Major presentations on targeted therapies included:
|+||Waiting to Exhale as Three Distinct Checkpoint Combinations Read Out in First-Line Non-Squamous NSCLC at AACR 2018|
|+||Keytruda® Poised for Another Knockout as Chemotherapy Combination Expands its Reach to Squamous Histology in First-Line NSCLC at ASCO 2018|
|+||For Cyramza®, a Small Portion of the Hepatocellular Carcinoma Market is in Reach for Patients with High Baseline Alpha-Fetoprotein Expression|
Experts from Kantar Health discuss these three important stories and offer their insights as to how physicians will apply the research they heard. Their full commentary can be found in our report.
Kantar Health provides both the research and consulting services you need to support your business decisions across the product lifecycle for cancer therapies. We have earned our oncology expert status because of the proprietary material we publish on cancer epidemiology, trends in oncology market access, oncology pipeline potential and treatment trends that help our clients with their business issues.
For more information, contact us at email@example.com
Complete the form below and we'll email you the report.